Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Thomas, Ryckewaert"'
Autor:
Manuel Rodrigues, Toulsie Ramtohul, Aurore Rampanou, José Luis Sandoval, Alexandre Houy, Vincent Servois, Léah Mailly-Giacchetti, Gaelle Pierron, Anne Vincent-Salomon, Nathalie Cassoux, Pascale Mariani, Caroline Dutriaux, Marc Pracht, Thomas Ryckewaert, Jean-Emmanuel Kurtz, Sergio Roman-Roman, Sophie Piperno-Neumann, François-Clément Bidard, Marc-Henri Stern, Shufang Renault
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive mar
Externí odkaz:
https://doaj.org/article/7a7c81a35eee4eb6a90455852698d2be
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
We reviewed all fully published clinical trials assessing anti-angiogenic agents in sarcoma patients (last issue, January 13, 2020). Anti-angiogenic macromolecules (e.g., bevacizumab or ombrabulin) provide disappointing results. Many multikinase inhi
Externí odkaz:
https://doaj.org/article/830c492b42a246b79f716321665ba867
Autor:
Loïc Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Isabelle Ray-Coquard, Axel Le Cesne, Emmanuelle Bompas, Jean-Yves Blay, Antoine Italiano, Olivier Mir, Thomas Ryckewaert, Yves Toiron, Luc Camoin, Anthony Goncalves, Nicolas Penel, Marie-Cécile Le Deley
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. Methods Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). T
Externí odkaz:
https://doaj.org/article/8bc9c15293a74110ae91f43eb5bfec0e
Autor:
Fabio Conforti, Alessandro Gronchi, Nicholas Penel, Robin L. Jones, Javier M. Broto, Isabella Sala, Vincenzo Bagnardi, Andrea Napolitano, Laura Pala, Elisabetta Pennacchioli, Chiara Catania, Paola Queirolo, Giovanni Grigani, Alessandra Merlini, Silvia Stacchiotti, Alessandro Comandone, Bruno Vincenzi, Vittorio Quagliuolo, Alexia Bertuzzi, Antonella Boglione, Elena Palassini, Giacomo G. Baldi, Jean-Yves Blay, Thomas Ryckewaert, Maud Toulmonde, Antoine Italiano, Axel Le Cesne, Isabelle Ray-Coquard, Josefina Cruz, Carmen N. Hernández-León, Javier M. Trufero, David da Silva Moura, Nadia H. Muñiz, Tommaso De Pas
Publikováno v:
European Journal of Cancer. 171:183-192
Background: We retrospectively investigated the role of (neo)adjuvant chemotherapy in patients with primary, localized angiosarcoma. Methods: We selected all patients with primary, localized angiosarcoma, who had received radical surgery between Janu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eff8d0ebf3e087d9aa3c54f3a8c1554
https://doi.org/10.1016/j.ejca.2022.04.030
https://doi.org/10.1016/j.ejca.2022.04.030
Autor:
Stéphane Champiat, Hélène Salaün, Francesca Lucibello, Jean-Yves Scoazec, Benjamin Besse, Ana Ines Lalanne, Etienne Rouleau, Nolwenn Metzger, Mathilde Saint-Ghislain, Thomas Ryckewaert, Sophie Gardrat, Raymond Barnhill, Nathalie Cassoux, Marc-Henri Stern, Olivier Lantz, Leanne de Koning, Aurélien Marabelle, Manuel Rodrigues
Publikováno v:
JCO Precision Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93326ad9c7e4e2c89b2af2fe7fc2e183
https://doi.org/10.1200/po.22.00363
https://doi.org/10.1200/po.22.00363
Autor:
Fabio Conforti, Alessandro Gronchi, Nicholas Penel, Robin L. Jones, Javier M. Broto, Isabella Sala, Vincenzo Bagnardi, Andrea Napolitano, Laura Pala, Elisabetta Pennacchioli, Chiara Catania, Paola Queirolo, Giovanni Grigani, Alessandra Merlini, Silvia Stacchiotti, Alessandro Comandone, Bruno Vincenzi, Vittorio Quagliuolo, Alexia Bertuzzi, Antonella Boglione, Elena Palassini, Giacomo G. Baldi, Jean-Yves Blay, Thomas Ryckewaert, Maud Toulmonde, Antoine Italiano, Axel Le Cesne, Isabelle Ray-Coquard, Josefina Cruz, Carmen N. Hernández-León, Javier M. Trufero, David da Silva Moura, Nadia H. Muñiz, Tommaso De Pas
Publikováno v:
European Journal of Cancer. 184:197-198
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9dc67f116fdaadb9c432b94de02864d
https://doi.org/10.1016/j.ejca.2022.11.027
https://doi.org/10.1016/j.ejca.2022.11.027
Autor:
Vincent Gamblin, Vincent Garcia, Capucine Aelbrecht-Meurisse, Diane Pannier, Nicolas Penel, Thomas Ryckewaert, Stéphane Aelbrecht
Publikováno v:
Bulletin du Cancer. 108:415-423
Resume La prise en charge de patients oncologiques, notamment hospitalises, peut amener a discuter, quasi quotidiennement les « Limitation et/ou Arret des Therapeutiques » (LAT). Nous proposons ici l’historique et la synthese des textes encadrant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4fc901d2e1cb7d346b400b4ed721394
https://doi.org/10.1016/j.bulcan.2020.11.020
https://doi.org/10.1016/j.bulcan.2020.11.020
Autor:
Yann‐Alexandre Vano, Letuan Phan, Gwenaelle Gravis, Iphigénie Korakis, Friederike Schlürmann, Denis Maillet, Mostefa Bennamoun, Nadine Houede, Delphine Topart, Delphine Borchiellini, Philippe Barthelemy, Raffaele Ratta, Thomas Ryckewaert, Ali Hasbini, Sophie Hans, Sheik Emambux, Sandra Cournier, Elena Braychenko, Réza‐Thierry Elaidi, Stéphane Oudard
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 2022, 151 (8), pp.1335-1344. ⟨10.1002/ijc.34126⟩
International Journal of Cancer, 2022, 151 (8), pp.1335-1344. ⟨10.1002/ijc.34126⟩
International audience; Nivolumab and cabozantinib are approved agents in mRCC patients after sunitinib/pazopanib (TKI) failure. However, the optimal sequence, cabozantinib then nivolumab (CN) or nivolumab then cabozantinib (NC), is still unknown. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa55d6650cf0c7bac8f95d4bcfa5b53b
https://amu.hal.science/hal-04084994
https://amu.hal.science/hal-04084994
Autor:
Charles Vauchier, Edouard Auclin, Philippe Barthélémy, Lucia Carril-Ajuria, Thomas Ryckewaert, Delphine Borchiellini, Zahra Castel-Ajgal, Mostefa Bennamoun, Luca Campedel, Antoine Thiery-Vuillemin, Elodie Coquan, Laurence Crouzet, Jean-François Berdah, Christine Chevreau, Raffaele Ratta, Aude Fléchon, Felix Lefort, Laurence Albiges, Marine Gross-Goupil, Yann-Alexandre Vano, Constance Thibault, Stéphane Oudard
Publikováno v:
Journal of oncology. 2022
Introduction. Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and subsequent therapies are needed. ICI rechallenge may be an option, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::249ac239380f4236ebd129621281b51e
https://pubmed.ncbi.nlm.nih.gov/35222642
https://pubmed.ncbi.nlm.nih.gov/35222642
Autor:
Jean-Yves Blay, Charles Honoré, Marick Laé, Audrey Monneur, Mehdi Brahmi, Fabien Reyal, Nicolas Isambert, Camille Chakiba, Esma Saada-Bouzid, Sophie Piperno-Neumann, Thomas Ryckewaert, Nelly Firmin, S. Thezenas, Christophe Sajous, Nicolas Penel, Sébastien Salas, Mathias Neron, Isabelle Ray-Coquard, François Bertucci, Florence Duffaud
Publikováno v:
Annals of Surgical Oncology
Annals of Surgical Oncology, Springer Verlag, 2019, ⟨10.1245/s10434-019-08097-x⟩
Annals of Surgical Oncology, 2019, ⟨10.1245/s10434-019-08097-x⟩
Annals of Surgical Oncology, Springer Verlag, 2019, ⟨10.1245/s10434-019-08097-x⟩
Annals of Surgical Oncology, 2019, ⟨10.1245/s10434-019-08097-x⟩
Metastatic phyllodes tumors have poor prognosis with median overall survival of 11.5 months. The objective of this study is to identify prognostic factors and the best options for management of metastatic malignant phyllode tumors (MMPTs). A multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ba96f9d9ea661ef2685a33df02f917
https://doi.org/10.1245/s10434-019-08097-x
https://doi.org/10.1245/s10434-019-08097-x